ARCHIVE

1st Qtr Business Results

August 21, 2006
Takeda:Domestic sales of ethical drugs: \135.6 billion (+5.1%)Overseas sales of ethical drugs: \161.0 billion (+17.3%)Sales of global strategic products: leuprorelin, \32.7 billion (+1.1%); lansoprazole, \40.2 billion (-13.8%); candesartan, \52.3 billion (+6.2%); pioglitazone, \84.0 billion (51.5%)Daiichi Sankyou:Overseas sales: \115,079 million (42.5%…

To read the full story

ARCHIVE

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

By Kohei Hori

Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…

By Philip Carrigan

A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…